Evidence map›Paper›PMID 19880437›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2010

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

Y L Kasamon, R J Jones, R A Brodsky, E J Fuchs, W Matsui, L Luznik, J D Powell, A L Blackford, A Goodrich, C D Gocke and 3 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Trial
  3. Article
  4. Article
  5. Isolated clonal cytogenetic abnormalities after high-dose therapy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Y L KasamonSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. Electronic address: ykasamo1@jhmi.edu.
R J JonesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
R A BrodskySidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
E J FuchsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
W MatsuiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
L LuznikSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
J D PowellSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
A L BlackfordSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
A GoodrichSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
C D GockeSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
R A AbramsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
R F AmbinderSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
I W FlinnSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Sidney Kimmel Comprehensive Cancer Center · US

Funding

Cancer Stem Cell Targeting in Multiple MyelomaR01CA127574 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATSUI, WILLIAM H · 2008 to 2012
$1.6M
Surgical Oncology Research Training ProgramT32CA009688 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 1992 to 2012
$1.4M
Novel Biologic Therapies for Hodgkin's LymphomaK23CA124465 · NCI · JOHNS HOPKINS UNIVERSITY · PI KASAMON, YVETTE L. · 2008 to 2012
$705k
NCI NIH HHS K23 CA124465NCI NIH HHS P50 CA09688NCI NIH HHS R01 CA127574NCI NIH HHS T32 CA009688
6 · The paper itself

Abstract

backgroundRituximab may improve transplant outcomes but may delay immunologic recovery. PATIENTS AND

methodsSeventy-seven patients with low-grade or mantle cell lymphoma received autologous stem-cell transplantation (ASCT) on a phase II study. Rituximab 375 mg/m(2) was administered 3 days before mobilization-dose cyclophosphamide, then weekly for four doses after count recovery from ASCT. Immune reconstitution was assessed.

resultsSixty percent of transplants occurred in first remission. Actuarial event-free survival (EFS) and overall survival (OS) were 60% and 73%, respectively, at 5 years, with 7.2-year median follow-up for OS in surviving patients. Median EFS was 8.3 years. Older age and transformed lymphomas were independently associated with inferior EFS, whereas day 60 lymphocyte counts did not predict EFS or late infections. Early and late transplant-related mortality was 1% and 8%, with secondary leukemia in two patients. B-cell counts recovered by 1-2 years; however, the median IgG level remained low at 2 years. Late-onset idiopathic neutropenia, generally inconsequential, was noted in 43%.

conclusionASCT with rituximab can produce durable remissions on follow-up out to 10 years. Major infections do not appear to be significantly increased or to be predicted by immune monitoring.

Indexed as

LymphomaLymphoma, Mantle-CellAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsCombined Modality TherapyDrug Administration ScheduleFemaleHumansImmune SystemImmunotherapyMaleMiddle AgedNeoplasm StagingAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsRituximab

Identifiers

PMID19880437
PMCPMC2875548
OpenAlexW2131369298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.